Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Les indicacions geogràfiques protegeixen el nom d’un producte originari d’una zona geogràfica, a la qual li deu una determinada qualitat, reputació o una altra característica. Descobreix què són, en què consisteix el seu procediment de registre i quins beneficis atorguen.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
158
resultados
Última actualización
30/11/2025 [07:23:00]
Resultados 125 a 150 de 158
Resumen de: CN120738038A
The invention discloses Weissella sinus PD13 for improving Alzheimer's disease and application of the Weissella sinus PD13, and relates to the technical field of biological medicine. Experiments prove that Weissella cibaria PD13 can improve spatial learning and memory impairment and autonomous exploration ability of AD model mice in Alzheimer's disease model mice induced by brain injection of A beta oligomer, and alleviate damage of neurons in hippocampal regions of the Alzheimer's disease model mice, so that the effect of protecting neurons is achieved, and the Weissella cibaria PD13 can be used for preparing drugs for treating Alzheimer's disease. According to the present invention, the Weissella cibaricola can effectively prevent and treat the Alzheimer's disease, increase the glutathione content and the superoxide dismutase enzyme activity of the mouse serum, and reduce the malondialdehyde content, such that the Weissella cibaricola has good prevention and treatment effects on the Alzheimer's disease, and the new approach is provided for developing the Alzheimer's disease-related drugs.
Resumen de: CN120732877A
The invention belongs to the field of biological medicine, and discloses application of mulberroside A in preparation of a medicine for preventing and treating Alzheimer's disease, and behavioral detection, histological and biochemical detection, cell experiment and biochemical index detection are carried out based on a constructed animal model. It is determined that the medicine prepared from mulberroside A can improve the new and old object recognition ability, improve spatial memory and cognitive functions, reduce loss of hippocampus and cortical neurons, regulate hippocampus and cortical cholinergic metabolism, up-regulate the expression ability of BDNF and CREB of hippocampus and cortical, enhance the cholinergic system function of N2a/APP695 cells and reduce oxidative damage. The mulberroside A has a remarkable effect on treating and improving the Alzheimer disease, and is applied to preparation of the medicine for preventing and treating the Alzheimer disease.
Resumen de: CN120738037A
The invention discloses calf animal coccus PD13 for improving Alzheimer's disease and application of the calf animal coccus PD13, and relates to the technical field of biology. Experiments prove that in an Alzheimer's disease model mouse induced by injecting A beta oligomer into the brain, the Azococcus calvus PD13 can improve spatial learning and memory disorder and autonomous exploration ability of the AD model mouse and relieve damage to neurons in a hippocampal region of the Alzheimer's disease model mouse, so that the effect of protecting the neurons is achieved, and the Azococcus calvus PD13 can be used for preparing a medicine for treating the Alzheimer's disease. According to the present invention, with the application of the animal coccus calves, the content of glutathione in mouse serum and the enzyme activity of superoxide dismutase are increased, and the content of malondialdehyde is reduced, such that the animal coccus calves provides good prevention and treatment effects on the Alzheimer's disease, and the new approach is provided for developing the Alzheimer's disease-related drugs.
Resumen de: CN120732893A
The invention belongs to the technical field of biological medicine, and particularly relates to application of hUC-MSCs combined with CEF in preparation of anti-PD drugs. The research finds that the hUC-MSCs and the CEF are combined to treat the PD, and the treatment effect is better than that of single hUC-MSCs or CEF, especially the treatment effect of Parkinson patients accompanied by intestinal diseases. The composition plays a role through the following ways: 1) repairing an intestinal barrier, and reducing endotoxin and inflammatory factors from entering a whole body system; 2) abnormal aggregation and propagation of alpha-syn are directly inhibited; 3) the composition of intestinal flora is regulated, excessive proliferation of pro-inflammatory flora is inhibited, and generation and secretion of SCFAs are promoted; and (4) the microenvironment in the brain is improved, neuroinflammation is relieved, and neural restoration is promoted. The invention provides a new thought for treatment of Parkinson's disease.
Resumen de: CN120738299A
The invention belongs to the technical field of functional grease processing, and particularly relates to an enzymolysis preparation method and application of diglyceride with an effect of improving Alzheimer's disease. The method comprises the following steps: mixing low-erucic acid rapeseed oil, glycerol and water, and heating to obtain a pre-reaction mixture; adding compound enzyme for reaction, and then adding candida antarctica lipase B and pseudomonas fluorescens lipase for reaction; and after the reaction is completed, carrying out molecular distillation, collecting a light-phase product, carrying out adsorption filtration, and collecting filtrate to obtain the diglyceride oil. The compound enzyme is composed of rhizomucor miehei lipase, candida rugosa lipase and candida antarctica lipase B in a weight ratio of (2-4): 2: 1. According to the method, the content of diglyceride is effectively increased, the prepared composition has the efficacy of preventing and treating Alzheimer's disease, and the efficacy is shown as improvement of reaction capacity and cognitive function, inhibition of brain apoptosis and acetylcholin esterase, enhancement of SOD and CAT vitality and improvement of related gene expression.
Resumen de: AU2024238511A1
The present disclosure relates to biomarkers and uses thereof in methods for selecting a patient diagnosed with amyotrophic lateral sclerosis (ALS) for an ALS therapy. The present disclosure further relates to methods for identifying the severity of ALS in a patient, treating an ALS patient, and monitoring efficacy of an ALS treatment.
Resumen de: AU2024220937A1
Provided herein are compounds, phannaceutical compositions, and methods of use for reducing the amount or activity of SNCA mRNA in a cell or subject, and in certain instances reducing the amount of alpha-synuclein protein in a cell or subject. Such compounds, pharmaceutical compositions, and methods of use are useful to ameliorate at least one symptom or hallmark of a synucleinopathy. Such synucleinopathies include Parkinson's disease, dementia with Lewy bodies (DLB), diffuse Lewy body disease, Parkinson's disease dementia (PDD), pure autonomic failure, multiple system atrophy (MSA), neuronopathic Gaucher's disease, and Alzheimer's disease.
Resumen de: AU2025230659A1
Abstract Provided herein are compounds that inhibit HDAC6, a protein whose activity is associated with a variety of diseases (e.g., cancer, neurological disorders). Also provided are pharmaceutical compositions and kits comprising the compounds, and methods of treating HDAC6-related diseases and disorders (e.g., Alzheimer's disease, cancer) with the compounds in a subject, by administering the compounds and/or compositions described herein. Abstract Provided herein are compounds that inhibit HDAC6, a protein whose activity is associated with a variety of diseases (e.g., cancer, neurological disorders). Also provided are pharmaceutical compositions and kits comprising the compounds, and methods of treating HDAC6-related diseases and disorders (e.g., Alzheimer's disease, cancer) with the compounds in a subject, by administering the compounds and/or compositions described herein.
Resumen de: US2025302843A1
The invention provides novel dosing regimens for Leuco-Methylthioninium (LMT) compounds which maximise the proportion of subjects in which the MT concentration will exceed concentrations in which therapeutic efficacy in relation to treatment of neurodegenerative disorders such as Alzheimer's disease and rontotemporal dementias can be achieved, while maintaining a desirable clinical profile. Also provided are LMT-containing dosage units and other compositions.
Resumen de: US2025302864A1
Methods for the prevention or treatment of Alzheimer's disease in a human patient are disclosed comprising administering a hydroxypropyl-beta-cyclodextrin.
Resumen de: US2025304709A1
Multispecific binding molecules having a first binding domain targeting a blood brain barrier target and a second binding domain targeting a neuron target, astrocyte target and/or glial cell target, and uses thereof in aiding the treatment of central nervous system diseases including neurodegenerative diseases such as Alzheimer's disease, Huntington's disease, Parkinson's diseases, Progressive Supranuclear Palsy (PSP), Amyotrophic Lateral Sclerosis (ALS), Frontal Temporal Dementia (FTD), autism, catalepsy, encephalitis, migraine, and Tourette's.
Resumen de: US2025304958A1
This application includes methods for reducing axonal tau protein. Those methods include inhibiting the binding between MAPT mRNA and hnRNP R.
Resumen de: US2025302980A1
Described are RNAi agents, compositions that include RNAi agents, and methods for inhibition of a microtubule associated protein tau (MAPT) gene. The MAPT RNAi agents and RNAi agent conjugates disclosed herein inhibit the expression of a MAPT gene. The MAPT RNAi agents are conjugated to an antigen binding protein that may enable subcutaneous delivery of the RNAi agents by facilitating crossing of the blood brain barrier (BBB). Pharmaceutical compositions that include one or more MAPT RNAi agents, optionally with one or more additional therapeutics, are also described. Delivery of the described MAPT RNAi agents to central nervous system (CNS) tissue, in vivo, provides for inhibition of MAPT gene expression and a reduction in MAPT activity, which can provide a therapeutic benefit to subjects, including human subjects, for the treatment of various diseases including Alzheimer's disease, Frontotemporal lobar degeneration dementia (FTLD), Progressive supranuclear palsy, and other tauopathies.
Resumen de: US2025302851A1
The disclosure provides methods for treating a subject in need thereof comprising administering to the subject a therapeutically-effective dose of psilocybin. The methods described herein may be used to treat a variety of diseases, disorders, and conditions. For example, the methods may be used to treat neurocognitive disorders (e.g., Alzheimer's disease, Parkinson's disease), ADHD, Epilepsy, Autism, Sleep-wake disorders, Chronic pain, Inflammatory Disorders, IBD, Stroke, ALS, and/or Multiple Sclerosis.
Resumen de: US2025306037A1
The present disclosure relates to methods useful to identify subjects having an increased risk for conversion to mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and/or stage a subject prior to the onset of mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and/or identify subjects with Aβ amyloidosis and/or to identify subjects who should or should not undergo further testing or treatment for Aβ amyloidosis, as well as methods for treating subjects diagnosed with Aβ amyloidosis by the methods disclosed herein.
Resumen de: US2025304970A1
Provided herein are methods for decreasing Ataxin-2 mRNA expression. Such methods are useful to ameliorate symptoms of Ataxin-2 associated diseases. Such Ataxin-2 associated diseases include amyotrophic lateral sclerosis (ALS). Such symptoms include loss of motor function, reduced CMAP amplitude, denervation, and loss of motor neurons.
Resumen de: US2025304670A1
Antibody for human amyloid beta. Antibody selectively binds human amyloid beta 42 peptide over human amyloid beta 40 peptide. Antibodies specific for amyloid beta 42 as therapeutic agents for binding amyloid beta 42 peptide and treating conditions associated with amyloidosis, such as Alzheimer's disease.
Resumen de: WO2025201511A1
The present invention relates to an indazole derivative and a preparation method therefor and a use thereof. The indazole derivative can be used for LRRK2 kinase inhibition or for treating Parkinson's disease (PD).
Resumen de: WO2025207501A1
Crystals of an antibody that specifically binds to human tau protein phosphorylated at serine 413 are provided, as well as methods of producing such antibody crystals, compositions comprising the crystals, and uses of such compositions for treating a disease, e.g., Alzheimer's disease. Crystals suitable for X-ray diffraction are also provided, and the inventors herein have used such crystals to solve the three-dimensional structure of the antibody to 2.76 Å resolution.
Resumen de: WO2025201405A1
A pharmaceutical composition comprising at least three components selected from the group consisting of Compound A, Compound B, Compound C, and Compound D, and their use in treating a neurodegenerative disease (e.g., Alzheimer's disease) and improving cognition or memory.
Resumen de: WO2025207476A1
A method of treating amyotrophic lateral sclerosis (ALS), includes: determining for a patient diagnosed with ALS, a pre-treatment amount of neurofilament light chain (NfL) in the patient's serum or plasma; orally administering to the patient a first rho kinase inhibitor in a predetermined amount for a predetermined period of time; determining a post-treatment amount of NfL in the patient's serum or plasma; when the post-treatment of amount of NfL is determined to be lower than the pre-treatment amount of NfL, orally administering to the patient a second rho kinase inhibitor in a therapeutically effective amount for treating ALS; and when the post-treatment of amount of NfL is determined to be not lower than the pre-treatment amount of NfL, withholding administration of the second rho kinase inhibitor to the patient.
Resumen de: EP4624448A1
A 1-(cyclobutylidenemethyl)-2, 4, 5-trimethoxybenzene compound and a preparation method and use thereof are provided, belonging to the field of drug development technology. The prepared 1-(cyclobutylidenemethyl)-2, 4, 5-trimethoxybenzene compound may be used for the preparation of an antiepileptic drug and drugs for treatment and/or prevention of traumatic craniocerebral injury disorders, ischemic stroke, hemorrhagic stroke, and Parkinson's disease.
Resumen de: AU2024237252A1
Methods for preventing, limiting or delaying clinical motor progression in a subject with Parkinson's disease with low GCase activity, such as a PD patient with a pathogenic variant in the glucocerebrosidase 1 (GBA1) gene (GBA-PD) is provided, said methods comprising administering a therapeutically effective amount of 5,7-dimethyl-N-((1R,4R)-4- (pentyloxy)cyclohexyl)pyrazolol1,5-apyrimidine-3-carboxamide (Compound A), or a pharmaceutically acceptable salt thereof, to said subject.
Resumen de: AU2024232317A1
The present invention provides a pharmaceutical composition comprising metformin and glibenclamide for use in the treatment of Parkinson's disease. The invention also comprises a combined administration of metformin and glibenclamide. In a preferred embodiment, the administration is made through oral route.
Nº publicación: MX2025010782A 01/10/2025
Solicitante:
SANOFI [FR]
SANOFI
Resumen de: MX2025010782A
The present invention relates to a compound of formula (I) wherein n is 1 or 2, R1 is halogen, (C<sub>1</sub>-C<sub>4</sub>)alkyl, halo(C<sub>1</sub>-C<sub>4</sub>)alkyl, (C<sub>1</sub>-C<sub>4</sub>)alkoxy, halo(C<sub>1</sub>-C<sub>4</sub>)alkoxy, ethynyl, propargyl, or (C<sub>3</sub>-C<sub>6</sub>)cycloalkyl, or two R1 form a cyclopentane ring fused to the phenol; R2 and R3 represent H, cyano, ethynyl, propargyl, (C<sub>1</sub>-C<sub>4</sub>)alkyl, hydroxy(C<sub>1</sub>-C<sub>4</sub>)alkyl or a halo(C<sub>1</sub>-C<sub>4</sub>)alkyl, or R2 and R3 form together with the atoms connecting them a (C<sub>5</sub>- C<sub>6</sub>)carbocyclic ring fused to the pyridazine ring; R4 and R5 form together with N to which they are attached an optionally substituted 3-7 membered monocyclic heterocycloalkyl ring, 8-11 membered bicyclic heterocycloalkyl ring or 7-12 membered bicyclic heterocyclic spiro ring. The present invention also relates to a medicament and a pharmaceutical composition comprising said compound of formula (I), as well as their therapeutic uses, in particular as inhibitor of NOD-like receptor protein 3 inflammasome for treating for example Parkinson's disease or frontotemporal Dementia.
BOPI
Sede Electrónica
